What is the typical dosing for a clonidine (clonidine) patch for treating hypertension (high blood pressure) or attention deficit hyperactivity disorder (ADHD)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 1, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Clonidine Patch Dosing for Hypertension and ADHD

For hypertension, the clonidine patch is dosed at 0.1-0.3 mg applied once weekly, while for ADHD, the recommended dosing is not clearly established for the patch formulation, though oral clonidine is typically started at 0.1 mg at bedtime and titrated up to a maximum of 0.4 mg/day. 1, 2

Clonidine Patch for Hypertension

Dosing Guidelines

  • Starting dose: 0.1 mg patch applied once weekly to a hairless area of intact skin on the upper outer arm or chest 1, 3
  • Titration: If blood pressure reduction is not achieved after 1-2 weeks, increase dosage by:
    • Adding another 0.1 mg patch, or
    • Changing to a larger system (0.2 mg or 0.3 mg) 3
  • Maximum dose: Doses above two 0.3 mg patches are usually not associated with additional efficacy 3
  • Application site: Each new application should be on a different skin site from the previous location 3

Important Considerations

  • Clonidine patches are generally reserved as a last-line therapy for hypertension due to significant CNS adverse effects, especially in older adults 1
  • Onset of antihypertensive effect may not begin until 2-3 days after initial application 3
  • When switching from oral clonidine or other antihypertensive medications, gradual reduction of prior drug dosage is advised 3

Clonidine for ADHD

Oral Clonidine Dosing (Extended Release)

  • Starting dose: 0.1 mg tablet at bedtime 2
  • Titration: Can increase to twice-daily administration with careful uptitration 2
  • Maximum dose: 0.4 mg/day 2

Patch Formulation for ADHD

While specific patch dosing guidelines for ADHD are not as clearly established as for oral formulations, the same principles of starting low (0.1 mg patch weekly) and titrating based on response and tolerability would apply.

Safety Considerations and Monitoring

Common Side Effects

  • Somnolence/sedation
  • Fatigue
  • Irritability
  • Insomnia and nightmares
  • Dry mouth
  • Bradycardia
  • Hypotension 2

Warnings and Precautions

  • Abrupt discontinuation: Avoid sudden discontinuation as this may induce hypertensive crisis; clonidine must be tapered to avoid rebound hypertension 1
  • Skin reactions: About 23% of patients may experience skin reactions with the patch formulation 4
  • Cardiovascular effects: Monitor for hypotension, bradycardia, and cardiac conduction abnormalities 2

Special Populations

  • Renal impairment: Dosage must be adjusted according to the degree of impairment 3
  • Pregnancy: Limited data suggests clonidine is likely not associated with adverse pregnancy outcomes, but should be used with caution 2
  • Breastfeeding: Clonidine is found in human milk; monitor breastfed infants for drowsiness and hypotonia 2

Clinical Efficacy

  • For hypertension, clonidine patches provide smooth, predictable blood pressure reduction 4
  • For ADHD, symptomatic improvement typically begins after 2 weeks of treatment, with an effect size generally in the medium range, smaller than stimulants 2

Comparative Considerations

  • Compared to guanfacine, clonidine is approximately ten times more potent, has less specificity for alpha-2A receptors, and may have more sedative effects 2
  • Clonidine is generally considered a second-line treatment for ADHD after stimulants due to smaller effect size 2

Remember that the transdermal route offers the advantage of once-weekly dosing, which may improve medication adherence compared to daily oral administration.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Clonidine Extended Release for ADHD and Hypertension Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.